Monte Rosa Therapeutics Inc (nasdaq:GLUE) Share Price

Company Profile

Business description
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their most advanced product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
Contact
321 Harrison Avenue
Suite 900
BostonMA02118
USA
T: +1 617 949-2643
https://www.monterosatx.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
103

Recommended

These undervalued stocks of high-quality companies could be attractive investments today.

Margaret Giles | 17 March 2025

Ben Graham was the king of flipping deep value stocks. The best investment of his life came from something very different.

Joseph Taylor | 17 March 2025

These shares have surged in price in the last year but are significantly overvalued according to our analysts.

Morningstar | 16 March 2025

Index	Last price	Change	% Change
All Ordinaries	8,082.10	68.80	0.86%
CAC 40	8,053.08	24.80	0.31%
DAX 40	23,057.17	70.35	0.31%
Dow JONES (US)	41,488.19	674.62	1.65%
FTSE 100	8,643.48	11.15	0.13%
HKSE	24,145.57	185.59	0.77%
NASDAQ	17,754.09	451.07	2.61%
Nikkei 225	37,396.52	343.42	0.93%
NZX 50 Index	12,166.14	100.11	-0.82%
S&P 500	5,638.94	117.42	2.13%
S&P/ASX 200	7,854.10	64.40	0.83%
SSE Composite Index	3,426.13	6.57	0.19%